JAKARTA, 14 December 2020 - PT Bank Maybank Indonesia Tbk. (“Maybank Indonesia”) is the first bank in Indonesia to provide facilities to state-owned pharmaceutical products producer and distributor PT Bio Farma (Persero) for its central role in the response to COVID-19 through the procurement of vaccines.

The partnership between Maybank Indonesia, through its Sharia Business Unit, and PT Bio Farma (Persero) demonstrates the strong collaboration, cooperation and synergy between the Government and private sector, especially for efforts to tackle COVID-19 in Indonesia and simultaneously offer a Sharia product or services.
 
The Sharia-based omnibus line facility of USD 185 million or Rp 2.68 trillion has been channeled to Bio Farma, through several terms. These financing facilities include Sharia services, Musharakah Trade Financing and forward hedging.
 
Taswin Zakaria, President Director of Maybank Indonesia said, "It is an honor for Maybank Indonesia to actively participate in efforts to combat the COVID-19 pandemic in Indonesia. Our hope is that this collaboration can have a broad impact on society and particularly for the Government in accelerating the recovery of the national economy and investment climate in Indonesia."
 
Regarding the financing facilities, Ricky Antariksa, Director of Global Banking at Maybank Indonesia said,"In line with the Sharia First approach, Maybank Indonesia provides this financing solution with the aim of expanding the scope of utilization of Sharia-based financing in the Indonesian business world."
 
Regarding efforts to tackle the COVID-19 pandemic, Ricky said,"Ae assess that PT Bio Farma (Persero) has a structured procurement plan and a strong business network through its subsidiaries PT Kimia Farma Tbk. and PT Indofarma (Persero) Tbk. which will carry out the function of distribution to the community."

In an effort to tackle the COVID-19 pandemic in Indonesia, the Government through PT Bio Farma (Persero) will strive to meet domestic demand by preparing 15 million bulk vaccinations for the first phase.

Director of Finance and Business Partners at PT Bio Farma (Persero), I Gusti Ngurah Suharta Wijaya, earlier explained, "Currently, PT Bio Farma (Persero) is the holding company for pharmaceutical SOEs, and together with PT Kimia Farma Tbk. and PT Indofarma (Persero) Tbk. carries out business activities that focus on tackling the COVID-19 pandemic in Indonesia. Considering the breadth and scale of the pandemic response, we need solid and innovative banking partners to provide the right financial solutions. "
 
"We hope that this partnership with Maybank Indonesia can take be conducted productively in line with the vision and mission of the Government to help the people throughout this country recover from the pandemic," concluded Suharta.

******

Notes for editors:

PT Bank Maybank Indonesia, Tbk. (“Maybank Indonesia”) is one of the largest banks in Indonesia, with access to the regional and international network of Maybank Group. Maybank Indonesia provides a range of products and services, including comprehensive Sharia services, for individual and corporate customers through Community Financial Services (Retail Banking and Non-Retail Banking) and Global Banking, as well as automotive financing through subsidiaries WOM Finance (two-wheeled vehicles) and Maybank Finance (four-wheeled vehicles). Maybank Indonesia also continues to develop Digital Banking services and capacity through Mobile Banking, Internet Banking, Maybank M2U (internet banking-based mobile banking) and various other channels.

As of 30th Setpember 2020, Maybank Indonesia had 362 branches including Sharia branches, throughout Indonesia and one overseas branch (Mumbai, India), 22 Mobile Cash Vehicles and 1,480 ATMs including 80 CDM (Cash Deposit Machines) connected to over 20,000 ATMs as part of the ATM PRIMA, ATM BERSAMA, ALTO, CIRRUS network connected to 3,500 Maybank ATMs in Singapore, Malaysia and Brunei. By end of September 2020, Maybank Indonesia managed Rp116.6 trillion in customer deposits and Rp177.3 trillion in assets.

For more information, please contact:
Tommy Hersyaputera, Head, Corporate & Brand Communications
Email: CCommunications@maybank.co.id
Tel: +6221 2922-8888